Global Anticoagulant Drugs Industry Overview | By Product (NOACs, Heparin, Warfarin, Others), and Application (Hospital, Pharmacy, Other) - Global Market Opportunity and Current Growth Analysis 2019-2025
-
Product Code:
RP-ID-10079083 -
Published Date:
24 Feb 2020 -
Region:
Global
-
Pages:
110 -
Category:
Healthcare & Pharmaceuticals -
Publisher:
Pub-ID-27
Impact Analysis on the Growth of Market
Activating Probable Propositions Amidst COVID-19 Crisis
With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More
Antithrombotic is a medication that keeps the development of thrombus or clump. Antithrombotic and anticoagulant operators are drugs used to decrease the arrangement of blood clusters by lessening the body's ability to shape a blood coagulation. These medications demonstration by keeping the generation of nutrient K in the liver. Antiplatelet, anticoagulant, and thrombolytic operators are distinctive sorts of antithrombotic specialists that demonstration through various thickening procedures. Blood vessel and venous thrombosis, the two sorts of thrombosis, can be treated with antithrombotic drugs.
The three key reasons for thrombosis are hypercoagulability, anomalous stream of blood, and damage caused to endothelial cells of the vein divider. These causes result from hereditary conditions, idleness, smoking, vein harm, pregnancy, and heftiness. As of now, thrombosis and related issue including myocardial dead tissue, stroke, and pneumonic embolism are essentially treated with off-patent anticoagulant drugs viz. warfarin and heparin. The other type of antithrombotic drugs for example headache medicine is additionally off-patent. With a couple of licensed viable fixes accessible in the market, pharmaceutical organizations have sufficient chances to enhance new items. The new medications could be productive for them, as the expanding total populace would guarantee unfaltering increment in the interest for such life-sparing medications. The worldwide antithrombotic/anticoagulant drugs showcase is relied upon to observe high development amid the conjecture time frame, inferable from elements, for example, high accessibility of these medications and ceaseless conditions related with thrombosis that require long haul tranquilize organization.
Major market players in Anticoagulant Drugs Industry are Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, Novartis AG, GlaxoSmithKline plc, Genentech Inc., AstraZeneca plc, Eli Lilly & Company, Aspen Holdings, Portola Pharmaceuticals Inc. and brief information 6 more companies provided in the report.
Anticoagulant Drugs Industry Segmentation:
Anticoagulant Drugs Industry Overview, By Product
• NOACs
• Heparin
• Warfarin
• Others
Anticoagulant Drugs Industry Overview, By Application
• Hospital
• Pharmacy
• Other
Anticoagulant Drugs Industry Overview, By Region
North America
• USA
• Canada
Europe
• Germany
• U.K.
• France
• Italy
• Rest of Europe
APAC
• China
• India
• Japan
• Rest of Asia-Pacific
RoW
• Latin America
• Middle East & Africa
Table of Content
1. Introduction
1.1 Industry Vision
1.2 Limitations
1.3 Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.2. Industry Size Estimation
2.2.1. Bottoms-Up Approach
2.2.2. Top-Down Approach
2.2.3. Annual Turnover Process
2.3. Data Triangulation
2.4. Research Assumptions
2.4.1. Assumption
3. Executive Summary
4. Industry Overview
4.1. Introduction
4.2. Strength
4.3. Weakness
4.4. Opportunities
4.5. Threats
5. Industry Trends
5.1. Introduction
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Buyers
5.2.4. Bargaining Power of Suppliers
5.2.5. Intensity of Competitive Rivalry
6. Anticoagulant Drugs Industry, By Product
6.1. NOACs
6.2. Heparin
6.3. Warfarin
6.4. Others
7. Anticoagulant Drugs Industry, By Application
7.1. Hospital
7.2. Pharmacy
7.3. Other
8 Geographical Analysis
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. RoE
8.4. Asia Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. RoAPAC
8.5. RoW
8.5.1. Latin America
8.5.1.1. Brazil
8.5.1.2. Argentina
8.5.1.3. Rest of Latin America
8.5.2. Middle East and Africa
9. Company Profiles
9.1 Bayer
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Overview
9.1.4 Current Development
9.2. Bristol-Myers Squibb
9.3. Pfizer
9.4. Johnson & Johnson
9.5. Sanofi
9.6. Boehringer Ingelheim
9.7. Daiichi Sankyo
9.8. Novartis AG
9.9. GlaxoSmithKline plc
9.10. Genentech Inc.
9.11. AstraZeneca plc
9.12. Eli Lilly & Company
9.13. Aspen Holdings
9.14. Portola Pharmaceuticals Inc.
10 Competitive Analysis
10.1. Introduction
10.2. Industry Positioning of Key Players
10.3 Competitive Strategies Adopted by Leading Players
11. Appendix
11.1. Questionnaire
11.2. Available Customizations
11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)
1. Introduction
1.1 Industry Vision
1.2 Limitations
1.3 Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.2. Industry Size Estimation
2.2.1. Bottoms-Up Approach
2.2.2. Top-Down Approach
2.2.3. Annual Turnover Process
2.3. Data Triangulation
2.4. Research Assumptions
2.4.1. Assumption
3. Executive Summary
4. Industry Overview
4.1. Introduction
4.2. Strength
4.3. Weakness
4.4. Opportunities
4.5. Threats
5. Industry Trends
5.1. Introduction
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Buyers
5.2.4. Bargaining Power of Suppliers
5.2.5. Intensity of Competitive Rivalry
6. Anticoagulant Drugs Industry, By Product
6.1. NOACs
6.2. Heparin
6.3. Warfarin
6.4. Others
7. Anticoagulant Drugs Industry, By Application
7.1. Hospital
7.2. Pharmacy
7.3. Other
8 Geographical Analysis
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. RoE
8.4. Asia Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. RoAPAC
8.5. RoW
8.5.1. Latin America
8.5.1.1. Brazil
8.5.1.2. Argentina
8.5.1.3. Rest of Latin America
8.5.2. Middle East and Africa
9. Company Profiles
9.1 Bayer
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Overview
9.1.4 Current Development
9.2. Bristol-Myers Squibb
9.3. Pfizer
9.4. Johnson & Johnson
9.5. Sanofi
9.6. Boehringer Ingelheim
9.7. Daiichi Sankyo
9.8. Novartis AG
9.9. GlaxoSmithKline plc
9.10. Genentech Inc.
9.11. AstraZeneca plc
9.12. Eli Lilly & Company
9.13. Aspen Holdings
9.14. Portola Pharmaceuticals Inc.
10 Competitive Analysis
10.1. Introduction
10.2. Industry Positioning of Key Players
10.3 Competitive Strategies Adopted by Leading Players
11. Appendix
11.1. Questionnaire
11.2. Available Customizations
11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)
